P2B-012

Blokhin Cancer Research Center (Moscow, Russia) › P2B-012

P2B-012

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) Compared to Doxorubicin in Subjects With Metastatic, Locally Advanced, or Unresectable Soft Tissue Sarcoma · Phase II
Blokhin Cancer Research Center (Moscow, Russia) · Dr. Moreau
consented 2012-06-20

completed

AEs

4

Serious

1

Dropout signal

–

Adverse events

4

Grade 2 febrile neutropenia with onset in cycle 5 (2012-10-10); assessed as related to study drug (probable); resolved 2012-10-19.

moderate assessed

Grade 3 anaemia with onset in cycle 2 (2012-08-11); assessed as related to study drug (probable); resolved 2012-08-22; action: drug interrupted.

severe assessed

Grade 3 neutropenia with onset in cycle 2 (2012-08-10); assessed as related to study drug (probable); resolved 2012-08-15.

severe assessed

Grade 3 febrile neutropenia with onset in cycle 1 (2012-07-15); serious (hospitalization); assessed as related to study drug (probable); resolved 2012-07-23; action: dose reduced.

severe serious assessed

Data queries

0

No data queries. Open queries would appear here for this patient.